Tearsheet

Glaukos (GKOS)

Market Price (11/7/2025): $82.1 | Market Cap: $4.7 Bil
Sector: Health Care | Industry: Health Care Equipment

Glaukos (GKOS)

Market Price (11/7/2025): $82.1
Market Cap: $4.7 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 30%	Weak multi-year price returns 2Y Excs Rtn is -28%, 3Y Excs Rtn is -24%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -88 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -19%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%		Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5.9%
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.0%

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 30%
1	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%
2	Weak multi-year price returns 2Y Excs Rtn is -28%, 3Y Excs Rtn is -24%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -88 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -19%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -4.5%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5.9%
5	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.0%

Market Valuation & Key Metrics

	11/7/25	2024	2023	2022	2021
Share Price CYE	$82.10	$149.94	$79.49	$43.68	$44.44
Market Cap CYE ($ Bil)	4.7	8.3	3.9	2.1	2.1
Total Debt ($ Bil)	0.1	0.1	0.4	0.4	0.4
Total Cash ($ Bil)	0.3	0.3	0.3	0.4	0.4
Enterprise Value ($ Bil)	4.5	8.4	4.3	2.5	2.5
Valuation Ratios
P/S TTM	10.0	20.6	12.2	7.3	7.0
P/EBIT TTM	-57.6	-58.4	-32.1	-24.5	-57.5
P/E TTM	-53.8	-54.0	-28.6	-20.9	-41.6
Sector Ratios
P/S TTM (Sector)	3.9	3.5	4.0	4.6	7.3
P/EBIT TTM (Sector)	-1.5	-1.3	-1.3	-1.3	-2.7
P/E TTM (Sector)	-1.8	-1.5	-1.5	-1.3	-2.8

	11/7/25	2024	2023
Share Price CYE	$82.10	$149.94	$79.49
Market Cap CYE ($ Bil)	4.7	8.3	3.9
Total Debt ($ Bil)	0.1	0.1	0.4
Total Cash ($ Bil)	0.3	0.3	0.3
Enterprise Value ($ Bil)	4.5	8.4	4.3
Valuation Ratios
P/S TTM	10.0	20.6	12.2
P/EBIT TTM	-57.6	-58.4	-32.1
P/E TTM	-53.8	-54.0	-28.6
Sector Ratios
P/S TTM (Sector)	3.9	3.5	4.0
P/EBIT TTM (Sector)	-1.5	-1.3	-1.3
P/E TTM (Sector)	-1.8	-1.5	-1.5

	GKOS	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.5
Rev Chg Q	38.1%	7.1%
Rev Chg LTM	30.4%	6.0%
Rev Chg 3Y Avg	18.5%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-18.8%	18.8%
CFO/Rev LTM	-4.5%	20.5%
Net Inc Mgn	-18.6%	12.9%
VALUATION	VERY HIGH
P/S	10.0	3.1
P/CFO	-223.1	15.1
P/FCF	-170.7	19.7
P/E	-53.8	23.5
STABILITY	VERY GOOD
Debt/Equity	0.02	0.21
Cash/Assets	0.27	0.07

AI Generated Analysis | Feedback

null

GKOS Stock

Return (1M):

Factor Drivers of Stock Movement

The -7.1% change in GKOS stock from 8/7/2025 to 11/6/2025 was primarily driven by a -14.1% change in the company's P/S Multiple.

	8072025	11062025	Change
Stock Price ($)	88.00	81.79	-7.06%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	432.95	469.82	8.52%
P/S Multiple	11.63	9.99	-14.06%
Shares Outstanding (Mil)	57.20	57.40	-0.34%
Cumulative Contribution			-7.06%

LTM = Last Twelve Months as of date shown

The -9.7% change in GKOS stock from 5/8/2025 to 11/6/2025 was primarily driven by a -21.2% change in the company's P/S Multiple.

	5082025	11062025	Change
Stock Price ($)	90.54	81.79	-9.66%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	404.52	469.82	16.14%
P/S Multiple	12.68	9.99	-21.17%
Shares Outstanding (Mil)	56.64	57.40	-1.34%
Cumulative Contribution			-9.68%

LTM = Last Twelve Months as of date shown

The -41.8% change in GKOS stock from 11/6/2024 to 11/6/2025 was primarily driven by a -53.5% change in the company's P/S Multiple.

	11062024	11062025	Change
Stock Price ($)	140.64	81.79	-41.84%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	360.35	469.82	30.38%
P/S Multiple	21.48	9.99	-53.48%
Shares Outstanding (Mil)	55.04	57.40	-4.29%
Cumulative Contribution			-41.95%

LTM = Last Twelve Months as of date shown

The 73.8% change in GKOS stock from 11/7/2022 to 11/6/2025 was primarily driven by a 64.9% change in the company's Total Revenues ($ Mil).

	11072022	11062025	Change
Stock Price ($)	47.05	81.79	73.84%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	284.88	469.82	64.92%
P/S Multiple	7.86	9.99	27.06%
Shares Outstanding (Mil)	47.61	57.40	-20.55%
Cumulative Contribution			66.50%

LTM = Last Twelve Months as of date shown

Why The Stock Moved

AI Generated Analysis | Feedback

Here are five key points explaining Glaukos (GKOS) stock movement by -5% from July 31, 2025, to November 7, 2025: 1. Continued Unprofitability Despite Revenue Growth.
Despite reporting record net sales and significant year-over-year revenue increases in both Q2 and Q3 2025, Glaukos continued to post net losses and negative net margins. For example, in Q3 2025, the company reported a net loss of $16.2 million, or ($0.28) per diluted share, and maintained a negative net margin of 21.43%. This ongoing unprofitability can be a significant concern for investors, even with strong top-line growth.

2. Mixed Analyst Sentiment and Price Target Adjustments.
During the period, there were notable shifts in analyst sentiment and price targets. Zacks Research, for instance, lowered Glaukos from a "strong-buy" rating to a "hold" rating in August. Additionally, Truist Financial reduced its price objective on Glaukos shares from $126.00 to $120.00 in September. Such adjustments from analytical firms can influence investor perception and contribute to stock price declines.

3. Increased Operating Expenses.
Glaukos reported increased operating expenses, with both GAAP and non-GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses rising in Q3 2025. While these investments are crucial for pipeline advancement and commercialization, they also impact current profitability and can be viewed cautiously by investors focusing on near-term earnings.

4. Potential Lengthening of Cash Conversion Cycle.
The company's accounts receivable increased in Q3 2025, driven by higher iDose TR sales that included extended payment terms. This could signal a lengthening of the cash conversion cycle, which might be perceived as a less efficient use of capital and a potential drag on liquidity by some investors.

5. Subdued Stock Reaction to Positive Q3 Earnings and Guidance Raise.
Despite Glaukos beating Q3 2025 earnings per share and revenue estimates and raising its full-year 2025 net sales guidance, the stock traded down on the day of the announcement. This suggests that the positive financial news might have already been priced into the stock, or other underlying concerns outweighed the favorable results, leading to a negative market reaction.

Show less

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
GKOS Return	38%	-41%	-2%	82%	89%	-45%	50%
Peers Return	4%	12%	-30%	125%	3%	-1%	86%
S&P 500 Return	16%	27%	-19%	24%	23%	14%	108%
Monthly Win Rates [3]
GKOS Win Rate	75%	50%	58%	58%	75%	50%
Peers Win Rate	37%	42%	32%	47%	43%	51%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
GKOS Max Drawdown	-53%	-46%	-22%	0%	-4%	-50%
Peers Max Drawdown	-24%	-3%	-41%	-7%	-14%	-18%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: SYK, COO, LIVN, NPCE, CUPR. See GKOS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 11/6/2025 (YTD)

How Low Can It Go

Unique Key	Event	GKOS	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-64.3%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	180.3%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	698 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-63.6%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	174.7%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	258 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-53.1%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	113.2%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	280 days	120 days

Compare to SYK, COO, LIVN, NPCE, CUPR

In The Past

Glaukos's stock fell -64.3% during the 2022 Inflation Shock from a high on 4/28/2021. A -64.3% loss requires a 180.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Glaukos (GKOS)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

Better Bets than Glaukos (GKOS)

	GKOS	Better Performance than GKOS
Metric	Value	Industry (Health Care Equipment)
Rev Chg LTM	30.4%	MASI (38.5%), TMDX (41.2%), UFPT (41.0%), KMTS (113.4%), SMTI (34.3%)
Rev Chg 3Y Avg	18.5%	PODD (26.1%), GMED (44.7%), TMDX (105.9%), INSP (37.7%), UFPT (30.2%)
Op Mgn LTM	-18.8%	ABT (17.6%), ISRG (29.3%), BSX (19.2%), SYK (19.6%), MDT (19.4%)
CFO/Rev LTM	-4.5%	ABT (20.8%), ISRG (30.8%), BSX (23.9%), SYK (19.8%), MDT (20.9%)
FCF/Rev LTM	-5.9%	ABT (15.8%), ISRG (23.6%), BSX (18.7%), SYK (16.7%), MDT (15.5%)
Total Yield	-1.9%	ABT (8.3%), ISRG (1.4%), BSX (1.9%), SYK (3.1%), MDT (7.2%)

	GKOS	Better Performance than GKOS
Metric	Value	Sector (Health Care)
Rev Chg LTM	30.4%	LLY (36.8%), ALNY (53.2%), NTRA (44.4%), TEM (72.6%), BBIO (62.5%)
Rev Chg 3Y Avg	18.5%	LLY (23.4%), ALNY (51.4%), INSM (22.8%), NTRA (39.7%), PODD (26.1%)
Op Mgn LTM	-18.8%	LLY (43.0%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%), ABT (17.6%)
CFO/Rev LTM	-4.5%	LLY (20.5%), JNJ (26.3%), ABBV (35.0%), UNH (4.8%), ABT (20.8%)
FCF/Rev LTM	-5.9%	LLY (-0.1%), JNJ (20.3%), ABBV (33.0%), UNH (4.0%), ABT (15.8%)
Total Yield	-1.9%	LLY (2.2%), JNJ (8.3%), ABBV (3.6%), UNH (8.7%), ABT (8.3%)

	GKOS	Better Performance than GKOS
Metric	Value	All Other Sectors
Rev Chg LTM	30.4%	NVDA (71.6%), PLTR (47.2%), AMD (31.8%), MU (48.9%), APP (86.4%)
Rev Chg 3Y Avg	18.5%	NVDA (92.0%), AVGO (24.0%), BRK-B (19.8%), PLTR (29.3%), MU (20.3%)
Op Mgn LTM	-18.8%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM	-4.5%	NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM	-5.9%	NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-1.9%	NVDA (1.9%), AAPL (2.9%), MSFT (3.5%), GOOGL (3.9%), AMZN (2.7%)

		Best Bets In Health Care Sector
	GKOS	RPRX	HALO	DOCS	CPRX	BMY	MEDP	PBH	MRK	NBIX	ISRG
What You Pay
P/E	-53.6	23.0	13.5	46.4	11.8	15.7	38.5	15.0	11.2	36.0	71.1
P/EBIT	-57.3	11.1	10.5	47.6	9.9	9.5	32.9	9.2	9.3	26.4	69.4
What You Get
Rev Chg Q	38.1%	7.9%	22.1%	23.2%	15.3%	2.8%	23.7%	-3.4%	3.7%	27.8%	22.9%
Rev Chg LTM	30.4%	3.7%	31.2%	20.2%	25.6%	1.3%	13.9%	-0.0%	1.7%	19.6%	22.2%
Rev Chg 3Y Avg	18.5%	1.5%	29.0%	17.4%	46.5%	1.0%	19.9%	0.1%	2.9%	24.6%	16.3%
FCF/Rev 3Y Avg	-17.8%	115.2%	45.0%	42.7%	34.2%	29.0%	25.3%	21.7%	22.0%	21.1%	16.5%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Glaukos Earnings Notes
2	Glaukos Stock Fell 6.8% in a Week, What Now?	Return
3	Is Glaukos Stock Outperforming Its Rivals?	Peer Comparison
4	GKOS Dip Buy Analysis
5	Glaukos Total Shareholder Return (TSR): 88.6% in 2024 and 50.0% 3-yr compounded annual returns (above peer average)
6	Glaukos (GKOS) worth $6.1 Bil (down $-1.5 Bil), still more valuable than Celanese	Notification
7	Glaukos (GKOS) worth $6.1 Bil (down $-1.5 Bil), still more valuable than Celanese	Notification
8	Glaukos (GKOS) worth $6.1 Bil (down $-1.5 Bil), still more valuable than Celanese	Notification
9	Glaukos (GKOS) Operating Cash Flow Comparison	Financials
10	Glaukos (GKOS) Net Income Comparison	Financials
11	ARTICLES
12	What’s Next For Glaukos After A Large 35% Drop In A Week?		July 21st, 2021

	Title
0	DASHBOARDS
1	Glaukos Earnings Notes
2	Glaukos Stock Fell 6.8% in a Week, What Now?
3	Is Glaukos Stock Outperforming Its Rivals?
4	GKOS Dip Buy Analysis
5	Glaukos Total Shareholder Return (TSR): 88.6% in 2024 and 50.0% 3-yr compounded annual returns (above peer average)
6	Glaukos (GKOS) worth $6.1 Bil (down $-1.5 Bil), still more valuable than Celanese
7	Glaukos (GKOS) worth $6.1 Bil (down $-1.5 Bil), still more valuable than Celanese
8	Glaukos (GKOS) worth $6.1 Bil (down $-1.5 Bil), still more valuable than Celanese
9	Glaukos (GKOS) Operating Cash Flow Comparison
10	Glaukos (GKOS) Net Income Comparison
11	ARTICLES
12	What’s Next For Glaukos After A Large 35% Drop In A Week?

Trade Ideas

Select past ideas related to GKOS. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-6.2%	-6.2%	-6.2%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.3%	-0.3%	-0.3%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-13.4%	-13.4%	-13.4%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	0.6%	0.6%	-1.9%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.8%	7.8%	-7.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-6.2%	-6.2%	-6.2%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.3%	-0.3%	-0.3%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-13.4%	-13.4%	-13.4%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	0.6%	0.6%	-1.9%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.8%	7.8%	-7.0%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	1.6	35.9%	16.2%
GDEN	Golden Entertainment	0.7	34.3%	-7.2%
HAE	Haemonetics	3.2	32.3%	-14.0%
APPN	Appian	2.8	30.8%	16.3%
LFST	LifeStance Health	2.4	29.9%	-15.2%
IOVA	Iovance Biotherapeutics	0.8	27.6%	-68.8%
SKYT	SkyWater Technology	0.9	27.2%	35.6%
BHF	Brighthouse Financial	3.8	26.8%	36.8%
DDOG	Datadog	66.1	23.1%	33.5%
HCC	Warrior Met Coal	4.3	22.9%	50.5%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ASPN	Aspen Aerogels	0.3	-44.5%	-65.4%
ACVA	ACV Auctions	0.9	-37.5%	-76.4%
ELF	e.l.f. Beauty	4.3	-35.0%	-39.0%
CCOI	Cogent Communications	1.2	-34.9%	-65.5%
BLZE	Backblaze	0.3	-33.8%	2.7%
PRCH	Porch	1.1	-33.4%	116.1%
PRTH	Priority Technology	0.4	-30.1%	-58.7%
AOSL	Alpha & Omega Semiconductor	0.6	-27.5%	-46.9%
STKL	SunOpta	0.5	-26.6%	-49.9%
VAC	Marriott Vacations Worldwide	1.7	-26.4%	-43.0%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TERN	Terns Pharmaceuticals	1.7	123.7%	229.4%
CSIQ	Canadian Solar	1.8	49.1%	140.5%
BHF	Brighthouse Financial	3.8	43.8%	36.8%
GDEN	Golden Entertainment	0.7	39.4%	-7.2%
CSTL	Castle Biosciences	1.0	38.6%	25.9%
FSLY	Fastly	1.6	37.5%	16.2%
TDC	Teradata	2.7	35.5%	-9.1%
HAE	Haemonetics	3.2	34.2%	-14.0%
APPN	Appian	2.8	28.7%	16.3%
MTSR	Metsera	8.6	28.0%	81549900.0%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
SOC	Sable Offshore	0.4	-62.3%	-78.9%
QURE	uniQure	1.5	-59.5%	55.8%
DD	DuPont de Nemours	16.4	-51.9%	-47.8%
BHVN	Biohaven	0.9	-50.9%	-77.2%
ASPN	Aspen Aerogels	0.3	-45.4%	-65.4%
ACVA	ACV Auctions	0.9	-42.8%	-76.4%
SVV	Savers Value Village	1.2	-40.3%	-22.9%
BLZE	Backblaze	0.3	-40.2%	2.7%
CCOI	Cogent Communications	1.2	-38.0%	-65.5%
ELF	e.l.f. Beauty	4.3	-37.8%	-39.0%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
PRAX	Praxis Precision Medicines	3.7	217.5%	123.9%
VTYX	Ventyx Biosciences	0.7	141.8%	322.8%
INBX	Inhibrx Biosciences	1.3	141.0%	425.9%
TERN	Terns Pharmaceuticals	1.7	120.9%	229.4%
PUMP	ProPetro	1.1	88.9%	15.2%
CSIQ	Canadian Solar	1.8	87.1%	140.5%
REPL	Replimune	0.8	86.0%	-29.8%
VICR	Vicor	4.0	72.9%	84.2%
GLUE	Monte Rosa Therapeutics	1.1	68.7%	87.5%
ESTA	Establishment Labs	1.9	61.8%	40.9%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SOC	Sable Offshore	0.4	-75.7%	-78.9%
FMC	FMC	1.6	-57.3%	-72.1%
QURE	uniQure	1.5	-54.1%	55.8%
ONDS	Ondas	0.8	-53.4%	105.1%
FI	Fiserv	33.9	-51.3%	-70.0%
LRN	Stride	3.0	-51.2%	-32.1%
ASPN	Aspen Aerogels	0.3	-50.5%	-65.4%
DD	DuPont de Nemours	16.4	-50.0%	-47.8%
NTLA	Intellia Therapeutics	1.3	-49.7%	5.7%
ELF	e.l.f. Beauty	4.3	-47.2%	-39.0%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	1.6	35.9%	16.2%
GDEN	Golden Entertainment	0.7	34.3%	-7.2%
HAE	Haemonetics	3.2	32.3%	-14.0%
APPN	Appian	2.8	30.8%	16.3%
LFST	LifeStance Health	2.4	29.9%	-15.2%
IOVA	Iovance Biotherapeutics	0.8	27.6%	-68.8%
SKYT	SkyWater Technology	0.9	27.2%	35.6%
BHF	Brighthouse Financial	3.8	26.8%	36.8%
DDOG	Datadog	66.1	23.1%	33.5%
HCC	Warrior Met Coal	4.3	22.9%	50.5%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ASPN	Aspen Aerogels	0.3	-44.5%	-65.4%
ACVA	ACV Auctions	0.9	-37.5%	-76.4%
ELF	e.l.f. Beauty	4.3	-35.0%	-39.0%
CCOI	Cogent Communications	1.2	-34.9%	-65.5%
BLZE	Backblaze	0.3	-33.8%	2.7%
PRCH	Porch	1.1	-33.4%	116.1%
PRTH	Priority Technology	0.4	-30.1%	-58.7%
AOSL	Alpha & Omega Semiconductor	0.6	-27.5%	-46.9%
STKL	SunOpta	0.5	-26.6%	-49.9%
VAC	Marriott Vacations Worldwide	1.7	-26.4%	-43.0%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TERN	Terns Pharmaceuticals	1.7	123.7%	229.4%
CSIQ	Canadian Solar	1.8	49.1%	140.5%
BHF	Brighthouse Financial	3.8	43.8%	36.8%
GDEN	Golden Entertainment	0.7	39.4%	-7.2%
CSTL	Castle Biosciences	1.0	38.6%	25.9%
FSLY	Fastly	1.6	37.5%	16.2%
TDC	Teradata	2.7	35.5%	-9.1%
HAE	Haemonetics	3.2	34.2%	-14.0%
APPN	Appian	2.8	28.7%	16.3%
MTSR	Metsera	8.6	28.0%	81549900.0%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
SOC	Sable Offshore	0.4	-62.3%	-78.9%
QURE	uniQure	1.5	-59.5%	55.8%
DD	DuPont de Nemours	16.4	-51.9%	-47.8%
BHVN	Biohaven	0.9	-50.9%	-77.2%
ASPN	Aspen Aerogels	0.3	-45.4%	-65.4%
ACVA	ACV Auctions	0.9	-42.8%	-76.4%
SVV	Savers Value Village	1.2	-40.3%	-22.9%
BLZE	Backblaze	0.3	-40.2%	2.7%
CCOI	Cogent Communications	1.2	-38.0%	-65.5%
ELF	e.l.f. Beauty	4.3	-37.8%	-39.0%

Peer Comparisons for Glaukos

Financials

	GKOS	SYK	COO	LIVN	NPCE	CUPR	Median
Name	Glaukos	Stryker	Cooper C.	LivaNova	NeuroPace	Cuprina
Mkt Price	81.79	353.81	69.00	49.57	12.78	0.84	59.28
Mkt Cap	4.7	135.3	13.8	2.7	0.4	-	4.7
Rev LTM	470	24,381	4,046	1,349	95	-	1,349
Op Inc LTM	-88	4,785	741	194	-18	-	194
FCF LTM	-28	4,073	412	191	-17	-	191
FCF 3Y Avg	-61	3,282	274	103	-19	-	103
CFO LTM	-21	4,832	816	251	-16	-	251
CFO 3Y Avg	-48	3,952	665	150	-19	-	150

Growth & Margins

	GKOS	SYK	COO	LIVN	NPCE	CUPR	Median
Name	Glaukos	Stryker	Cooper C.	LivaNova	NeuroPace	Cuprina
Rev Chg LTM	30.4%	11.0%	6.4%	8.6%	24.1%	-	11.0%
Rev Chg 3Y Avg	18.5%	10.8%	7.9%	9.9%	29.6%	-	10.8%
Rev Chg Q	38.1%	10.2%	5.7%	12.5%	29.9%	-	12.5%
QoQ Delta Rev Chg LTM	8.5%	2.4%	1.4%	3.0%	7.1%	-	3.0%
Op Mgn LTM	-18.8%	19.6%	18.3%	14.4%	-19.2%	-	14.4%
Op Mgn 3Y Avg	-30.3%	19.5%	16.5%	8.3%	-34.2%	-	8.3%
QoQ Delta Op Mgn LTM	3.5%	0.0%	-0.7%	1.0%	3.2%	-	1.0%
CFO/Rev LTM	-4.5%	19.8%	20.2%	18.6%	-17.2%	-	18.6%
CFO/Rev 3Y Avg	-13.8%	17.8%	17.5%	11.6%	-26.3%	-	11.6%
FCF/Rev LTM	-5.9%	16.7%	10.2%	14.2%	-17.5%	-	10.2%
FCF/Rev 3Y Avg	-17.8%	14.7%	7.2%	7.9%	-26.7%	-	7.2%

Valuation

	GKOS	SYK	COO	LIVN	NPCE	CUPR	Median
Name	Glaukos	Stryker	Cooper C.	LivaNova	NeuroPace	Cuprina
Mkt Cap	4.7	135.3	13.8	2.7	0.4	-	4.7
P/S	10.0	5.5	3.4	2.0	4.5	-	4.5
P/EBIT	-57.3	28.3	19.1	-19.7	-26.6	-	-19.7
P/E	-53.6	46.0	33.7	-12.5	-17.7	-	-12.5
P/CFO	-222.2	28.0	16.8	10.8	-26.0	-	10.8
Total Yield	-1.9%	3.1%	3.0%	-8.0%	-5.7%	-	-1.9%
Dividend Yield	0.0%	0.9%	0.0%	0.0%	0.0%	-	0.0%
FCF Yield 3Y Avg	-1.3%	2.6%	1.7%	3.6%	-7.6%	-	1.7%
D/E	0.0	0.1	0.2	0.2	0.2	-	0.2
Net D/E	-0.0	0.1	0.2	-0.1	0.0	-	0.0

Returns

	GKOS	SYK	COO	LIVN	NPCE	CUPR	Median
Name	Glaukos	Stryker	Cooper C.	LivaNova	NeuroPace	Cuprina
1M Rtn	-2.7%	-4.2%	-0.0%	-4.9%	20.0%	-23.3%	-3.5%
3M Rtn	-7.1%	-5.8%	-0.3%	2.2%	43.3%	-89.9%	-3.0%
6M Rtn	-9.7%	-7.1%	-16.8%	12.5%	1.8%	-82.8%	-8.4%
12M Rtn	-41.8%	-3.3%	-33.5%	-4.9%	63.8%	-	-4.9%
3Y Rtn	73.8%	70.7%	2.0%	-0.5%	448.5%	-	70.7%
1M Excs Rtn	-6.1%	-5.2%	-1.3%	-6.6%	15.3%	-24.1%	-5.7%
3M Excs Rtn	-8.6%	-11.3%	-7.0%	-3.7%	37.1%	-94.9%	-7.8%
6M Excs Rtn	-28.3%	-25.7%	-35.4%	-6.2%	-16.8%	-101.5%	-27.0%
12M Excs Rtn	-55.4%	-20.3%	-51.8%	-16.5%	83.0%	-	-20.3%
3Y Excs Rtn	-24.4%	-8.7%	-75.3%	-68.3%	271.0%	-	-24.4%

Comparison Analyses

	Title
0	Is Glaukos Stock Outperforming Its Rivals?
1	Why GKOS With 66% Upside May Beat SYK?
2	With 67% Gains On The Table, GKOS May Outshine COO
3	Glaukos vs. iRhythm Technologies: With Return Forecast Of 138%, iRhythm Technologies Is A Better Bet
4	Glaukos vs. Vicor: With Return Forecast Of 48%, Glaukos Is A Better Bet
5	Glaukos vs. Varonis Systems: With Return Forecast Of 48%, Glaukos Is A Better Bet
6	Glaukos vs. Aerojet Rocketdyne: Similar Market Cap, But Glaukos Is A Better Bet
7	Glaukos vs. ABM Industries: Similar Market Cap, But Glaukos Is A Better Bet
8	Glaukos vs. AAON: Similar Market Cap, But Glaukos Is A Better Bet
9	Glaukos vs Kratos Defense & Security Solutions: Similar Market Cap; Which Stock Is A Better Bet?

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	10/31/2025	2/25/2025	2/23/2024	2/24/2023	2/28/2022	3/1/2021	3/2/2020
Key Financials
Total Revenue	470	383	315	283	294	225	237
EBITDA	-43	-96	-82	-49	-1	-84	-38
Operating Income	-88	-108	-124	-102	-53	-124	-47
Net Income	-88	-146	-135	-99	-50	-120	15
EPS	-1.54	-2.77	-2.78	-2.09	-1.07	-2.70	0.41
Growth Rates
Total Revenue Growth	30.4%	21.9%	11.3%	-3.8%	30.7%	-5.1%	30.7%
EBITDA Growth	55.8%	-16.5%	-68.4%	-3208.2%	98.2%	-122.3%	-516.1%
Operating Income Growth	23.9%	12.6%	-20.9%	-93.5%	57.2%	-165.4%	-258.0%
Net Income Growth	41.4%	-8.7%	-35.8%	-100.0%	58.8%	-880.3%	219.1%
Margins
EBITDA Margin	-9.1%	-24.9%	-26.1%	-17.2%	-0.5%	-37.2%	-15.9%
Operating Income Margin	-18.8%	-28.2%	-39.3%	-36.2%	-18.0%	-54.9%	-19.6%
Net Income Margin	-18.6%	-38.2%	-42.8%	-35.1%	-16.9%	-53.5%	6.5%
Cash & Debt
Total Cash	274	319	295	353	414	404	174
Total Debt	104	103	384	382	382	271	73
Net Debt / (Cash)	-169	-216	88	30	-32	-134	-101
Cash Flows
Net Cash from Operations	-21	-61	-58	-33	25	-23	-0
Free Cash from Operations	-28	-68	-78	-63	-23	-30	-5
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	10/31/2025	8/4/2025	5/1/2025	2/25/2025	11/5/2024	8/2/2024	5/3/2024	2/23/2024	11/1/2023	8/2/2023	5/4/2023	2/24/2023
Key Financials Quarterly
Total Revenue	134	124	107	105	97	96	86	82	78	80	74	71
Ebitda	-5	-9	-7	-22	-10	-37	-27	-24	-15	-22	-21	-19
Operating Income	-16	-23	-21	-29	-25	-27	-27	-37	-28	-26	-33	-34
Net Income	-16	-20	-18	-34	-21	-51	-41	-37	-30	-33	-35	-31
EPS	-0.28	-0.34	-0.32	-0.60	-0.39	-1.00	-0.82	-0.75	-0.63	-0.68	-0.72	-0.66
Key Financials TTM
Total Revenue TTM	470	433	405	383	360	342	326	315	304	297	289	283
Ebitda TTM	-43	-48	-76	-96	-97	-103	-88	-82	-77	-74	-88	-49
Operating Income TTM	-88	-97	-101	-108	-116	-119	-118	-124	-121	-114	-115	-102
Net Income TTM	-88	-93	-124	-146	-150	-159	-141	-135	-129	-126	-139	-99
Growth Rates Quarterly
Total Revenue Growth	38.1%	29.7%	24.6%	28.1%	23.9%	19.0%	15.9%	15.6%	9.5%	10.6%	9.2%	-2.7%
EBITDA Growth	51.3%	76.5%	72.8%	5.8%	38.0%	-70.1%	-25.9%	-27.4%	-22.0%	39.2%	-219.3%	-84.5%
Operating Income Growth	33.6%	17.4%	24.4%	21.7%	12.0%	-5.4%	17.1%	-8.6%	-29.6%	2.6%	-63.3%	-88.8%
Net Income Growth	24.2%	61.1%	55.6%	8.7%	29.7%	-54.0%	-17.9%	-16.9%	-10.4%	27.9%	-744.0%	-43.8%
Margins Quarterly
EBITDA Margin	-3.5%	-7.0%	-6.9%	-21.1%	-9.8%	-38.5%	-31.6%	-28.7%	-19.7%	-26.9%	-29.1%	-26.1%
Operating Income Margin	-12.3%	-18.3%	-19.4%	-27.2%	-25.5%	-28.7%	-31.9%	-44.5%	-35.9%	-32.4%	-44.6%	-47.4%
Net Income Margin	-12.2%	-15.8%	-17.0%	-31.8%	-22.1%	-52.8%	-47.7%	-44.7%	-39.0%	-40.8%	-46.9%	-44.2%
Cash & Debt
Total Cash	274	275	299	319	262	262	273	295	301	304	318	353
Total Debt	104	105	105	103	157	157	384	384	384	384	383	382
Net Debt / (Cash)	-169	-170	-193	-216	-105	-105	111	88	83	80	65	30
Cash Flows Quarterly
FCF from Operations	-10	7	-19	1	-10	-18	-34	-11	-8	-8	-31	-4
Cash Flows TTM
FCF from Operations TTM	-21	-21	-46	-61	-72	-71	-61	-58	-51	-70	-74	-33
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-4.7%	-6.6%	-6.2%	-8.8%	-7.7%	-8.8%	-9.1%	-12.7%	-10.0%	-9.5%	-12.3%	-13.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-6.3%	-7.0%	-7.6%	-8.3%	-9.1%	-9.6%	-9.8%	-10.8%	-10.8%	-10.4%	-10.7%	-10.0%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Glaucoma	237	214	232	179	231
Corneal Health	78	69	62	46	6
Total	315	283	294	225	237

Price Behavior

Price Behavior

Market Price	$81.79
Market Cap ($ Bil)	4.7
First Trading Date	06/25/2015
Distance from 52W High	-49.3%
	50 Days	200 Days
DMA Price	$84.67	$99.91
DMA Trend	down	down
Distance from DMA	-3.4%	-18.1%
	3M	1YR
Volatility	50.6%	52.6%
Downside Capture	45.59	159.53
Upside Capture	-6.12	82.72
Correlation (SPY)	3.8%	52.1%

GKOS Betas & Captures as of 10/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-0.30	-0.33	0.17	0.85	1.42	1.19
Up Beta	-1.87	-1.32	0.32	1.14	1.42	1.09
Down Beta	0.70	0.30	0.19	0.35	1.63	1.43
Up Capture	17%	-59%	15%	67%	85%	141%
Bmk +ve Days	14	27	37	74	145	425
Stock +ve Days	13	21	33	65	120	381
Down Capture	-113%	-10%	10%	109%	130%	104%
Bmk -ve Days	9	17	28	53	106	327
Stock -ve Days	10	23	32	60	129	370

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of GKOS With Other Asset Classes (Last 1Y)
	GKOS	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-37.9%	0.1%	18.5%	45.0%	2.2%	-1.7%	50.6%
Annualized Volatility	53.4%	17.0%	19.6%	19.9%	16.2%	17.9%	37.1%
Sharpe Ratio	-0.70	-0.16	0.74	1.76	-0.05	-0.24	0.86
Correlation With Other Assets		34.4%	51.9%	-0.3%	18.9%	34.2%	31.9%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of GKOS With Other Asset Classes (Last 5Y)
	GKOS	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	7.3%	9.1%	16.8%	15.9%	13.8%	6.7%	50.4%
Annualized Volatility	48.7%	14.5%	17.1%	15.6%	18.9%	19.1%	49.2%
Sharpe Ratio	0.32	0.45	0.80	0.81	0.61	0.27	0.77
Correlation With Other Assets		31.4%	41.8%	2.6%	9.7%	33.6%	19.7%

Based On 10-Year Data

		Comparison of GKOS With Other Asset Classes (Last 10Y)
	GKOS	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	15.0%	9.2%	14.3%	12.8%	5.1%	5.0%	78.6%
Annualized Volatility	53.4%	16.7%	18.0%	14.7%	17.7%	20.9%	56.2%
Sharpe Ratio	0.48	0.45	0.68	0.71	0.22	0.21	0.96
Correlation With Other Assets		36.3%	41.5%	0.9%	14.1%	32.6%	11.0%

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	2,407,704
Short Interest: % Change Since 9302025	-23.6%
Average Daily Volume	725,920
Days-to-Cover Short Interest	3.32
Basic Shares Quantity	57,398,000
Short % of Basic Shares	4.2%

Returns Analyses

	Title
0	Glaukos Stock Fell 6.8% in a Week, What Now?
1	Glaukos Stock Return Comparison
2	Glaukos (GKOS) Stock Has Very Small Chance Of Rise In The Next One Month
3	[10/15/2021] Glaukos (GKOS) Stock Price Forecast: AI Forecasts GKOS Stock Price To Be Around $46.30 In A Month (Up 3.3%)
4	Glaukos Total Shareholder Return (TSR): -1.7% in 2022 and -7.1% 3-yr returns (above peer average)
5	Glaukos (GKOS) Stock Return: AI Predicts GKOS Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
10/29/2025	13.9%	9.4%
7/30/2025	-8.5%	-5.9%	2.7%
2/20/2025	-20.0%	-24.8%	-35.0%
11/4/2024	-2.7%	8.9%	5.2%
7/31/2024	0.4%	-1.1%	13.2%
5/1/2024	6.2%	8.1%	14.0%
2/21/2024	-1.4%	-3.0%	-5.7%
11/1/2023	-7.6%	-7.6%	-6.2%
...
SUMMARY STATS
# Positive	10	7	10
# Negative	13	16	13
Median Positive	3.7%	9.4%	12.7%
Median Negative	-5.6%	-7.1%	-7.8%
Max Positive	13.9%	27.4%	33.7%
Max Negative	-28.5%	-35.1%	-45.8%

	Forward Returns
10/29/2025	13.9%	9.4%
7/30/2025	-8.5%	-5.9%	2.7%
2/20/2025	-20.0%	-24.8%	-35.0%
11/4/2024	-2.7%	8.9%	5.2%
7/31/2024	0.4%	-1.1%	13.2%
5/1/2024	6.2%	8.1%	14.0%
2/21/2024	-1.4%	-3.0%	-5.7%
11/1/2023	-7.6%	-7.6%	-6.2%
8/2/2023	-0.4%	-3.0%	0.6%
5/3/2023	8.8%	27.4%	33.7%
2/22/2023	-3.1%	-3.8%	-4.4%
11/2/2022	-9.6%	-7.7%	-10.5%
8/3/2022	0.3%	-5.6%	-8.5%
5/4/2022	-5.5%	-26.6%	-9.7%
2/22/2022	3.9%	12.1%	12.2%
11/4/2021	3.6%	-6.7%	-24.7%
8/5/2021	0.1%	-2.8%	16.0%
2/25/2021	2.7%	-9.1%	-7.1%
11/5/2020	6.7%	15.3%	21.8%
8/6/2020	-11.5%	-13.5%	-1.5%
5/7/2020	-3.1%	-15.9%	4.8%
2/27/2020	-28.5%	-35.1%	-45.8%
11/6/2019	-5.6%	0.4%	-4.0%
SUMMARY STATS
# Positive	10	7	10
# Negative	13	16	13
Median Positive	3.7%	9.4%	12.7%
Median Negative	-5.6%	-7.1%	-7.8%
Max Positive	13.9%	27.4%	33.7%
Max Negative	-28.5%	-35.1%	-45.8%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	10312025	10-Q 9/30/2025
6302025	8042025	10-Q 6/30/2025
3312025	5012025	10-Q 3/31/2025
12312024	2252025	10-K 12/31/2024
9302024	11052024	10-Q 9/30/2024
6302024	8022024	10-Q 6/30/2024
3312024	5032024	10-Q 3/31/2024
12312023	2232024	10-K 12/31/2023
9302023	11012023	10-Q 9/30/2023
6302023	8022023	10-Q 6/30/2023
3312023	5042023	10-Q 3/31/2023
12312022	2242023	10-K 12/31/2022
9302022	11042022	10-Q 9/30/2022
6302022	8052022	10-Q 6/30/2022
3312022	5052022	10-Q 3/31/2022
12312021	2282022	10-K 12/31/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Navratil Tomas	CHIEF DEVELOPMENT OFFICER	9242025	Sell	82.79	23	1,904	6,365,226	Form
1	Navratil Tomas	CHIEF DEVELOPMENT OFFICER	2192025	Sell	147.14	3,416	502,630	10,658,380	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Glaukos (GKOS)

Market Price (11/7/2025): $82.1 | Market Cap: $4.7 BilSector: Health Care | Industry: Health Care Equipment

Glaukos (GKOS)

Market Price (11/7/2025): $82.1Market Cap: $4.7 BilSector: Health CareIndustry: Health Care Equipment

Market Valuation & Key Metrics

GKOS Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Glaukos (GKOS)

Interactive Breakdown

Better Bets than Glaukos (GKOS)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Glaukos

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (11/7/2025): $82.1 | Market Cap: $4.7 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (11/7/2025): $82.1
Market Cap: $4.7 Bil
Sector: Health Care
Industry: Health Care Equipment